This disclosure provides invention of the of a cancer drug , the combination of the iron oxide nanocage and engineered destabilized 3’UTR of ERBB2 and MYC as a safe and therapeutically effective means to target ERBB2 and MYC driven cancers which inhibited both the primary metastatic tumors in-vivo in mouse model of c-MYC triple negative breast cancer (MDAMB231) and ERBB2 driven cancers (drug resistant EGFRT790M non-small cell lung cancer NCIH1975) and ERBB2+ trastuzumab drug resistant BT474 clone 5.
Key Words: Engineered destabilized 3’UTR, c-MYC, ERBB2 and iron oxide nanocage, tumor and metastasis inhibition
UTR Therapeutics & Hunter College
Chidiebere U Awah & Hiroshi Matsui chidi@utrtherapeutics.com, chidiebereawah@gmail.com, hmatsui@hunter.cuny.edu
For more information or to license this innovation:
- Log In
to view the innovation's details
- Sign Up
with discount code "ECOS"
